Breakpoint Therapeutics GmbH

Breakpoint Therapeutics is a newly founded company that will discover and develop new anti-cancer drugs.

By targeting the DNA damage response (“DDR”) in cancer cells, Breakpoint Therapeutics aims to advance to clinical development first-in-class oncology drugs that interfere with DNA repair and replication stress tolerance
pathways. Our mission is to develop drugs that succeed and complement PARP inhibitors and
facilitate the cure of therapy resistant cancers.

Breakpoint Therapeutics GmbH is a spin-off company of Evotec SE and backed by a €30 million
financing round led by Medicxi, Taiho Ventures and Evotec. The company is jointly managed by Dr
Daniel Speidel and Dr Jonathan Hollick.